Who Buys Extract from India — 591 Importers Behind a $12.1M Market

The 591 buyers of "Extract" from India can be categorized into several segments:

1. Distributors: Entities that purchase products to resell to retailers or end-users. For instance, REGENCY PHARMA LIMITED in Mauritius, the top buyer with imports totaling $0.81 million, likely operates as a distributor, supplying various healthcare providers.

2. Hospital Groups: Large healthcare institutions procuring directly for patient care. While specific hospital groups are not identified among the top buyers, it's common for such entities to source directly to ensure consistent supply.

3. Retail Chains: Pharmacy chains or health stores purchasing for retail sale. UNAHCO INC in the Philippines, importing $0.59 million worth of "Extract," may represent this segment, distributing products through its retail network.

4. Government Procurement: National health agencies or international organizations like UNICEF and the Global Fund procuring for public health programs. The data does not specify such buyers, but they typically engage in large-volume, tender-based purchasing.

5. Re-exporters: Companies importing goods to export them to other markets. INOVA PHARMACEUTICALS (SINGAPORE) PT, with imports of $0.40 million, might function as a re-exporter, leveraging Singapore's strategic location.

6. Contract Manufacturers: Firms importing raw materials or semi-finished products for further processing. NATURELLE LLC in the United Arab Emirates, importing $0.30 million, could be involved in such activities, producing finished goods for various markets.

Typical buying behaviors vary: distributors and retail chains often place regular, moderate-sized orders to maintain inventory levels, while government agencies and hospital groups may engage in bulk purchasing through tenders to meet large-scale needs. Re-exporters and contract manufacturers' order patterns depend on downstream demand and production schedules.

For the top five importing countries, the import regulations for "Extract" (HS Code 30049099) are as follows:

The demand for "Extract" in importing countries is influenced by several factors:

1. Disease Prevalence: High incidences of diseases treatable by "Extract" drive demand. For example, if "Extract" is used in managing cardiovascular conditions, countries with rising cases of heart disease would exhibit increased demand.

2. Government Healthcare Programs: Initiatives aimed at improving public health, such as the Philippines' Universal Health Care Act enacted in 2019, expand access to medications, thereby boosting demand for pharmaceutical imports.

3. Universal Health Coverage Expansion: Countries striving to achieve universal health coverage, like Myanmar's National Health Plan (2017-2021), aim to provide essential medicines to a larger population, increasing the need for imports.

4. WHO Essential Medicines List Procurement: Inclusion of "Extract" in the WHO Essential Medicines List prompts countries to procure it for public health facilities, ensuring availability for critical treatments.

5. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders to ensure cost-effectiveness and supply security. The presence of 591 buyers across 109 countries indicates a competitive market, with opportunities for suppliers to engage in such procurement processes.

Understanding these demand drivers enables suppliers to tailor their strategies, ensuring they meet the specific needs of each market and capitalize on emerging opportunities.

The 591 buyers of "Extract" from India can be categorized into several segments:

1. Distributors: Entities that purchase products to resell to retailers or end-users. For instance, REGENCY PHARMA LIMITED in Mauritius, the top buyer with imports totaling $0.81 million, likely operates as a distributor, supplying various healthcare providers.

2. Hospital Groups: Large healthcare institutions procuring directly for patient care. While specific hospital groups are not identified among the top buyers, it's common for such entities to source directly to ensure consistent supply.

3. Retail Chains: Pharmacy chains or health stores purchasing for retail sale. UNAHCO INC in the Philippines, importing $0.59 million worth of "Extract," may represent this segment, distributing products through its retail network.

4. Government Procurement: National health agencies or international organizations like UNICEF and the Global Fund procuring for public health programs. The data does not specify such buyers, but they typically engage in large-volume, tender-based purchasing.

5. Re-exporters: Companies importing goods to export them to other markets. INOVA PHARMACEUTICALS (SINGAPORE) PT, with imports of $0.40 million, might function as a re-exporter, leveraging Singapore's strategic location.

6. Contract Manufacturers: Firms importing raw materials or semi-finished products for further processing. NATURELLE LLC in the United Arab Emirates, importing $0.30 million, could be involved in such activities, producing finished goods for various markets.

Typical buying behaviors vary: distributors and retail chains often place regular, moderate-sized orders to maintain inventory levels, while government agencies and hospital groups may engage in bulk purchasing through tenders to meet large-scale needs. Re-exporters and contract manufacturers' order patterns depend on downstream demand and production schedules.

For the top five importing countries, the import regulations for "Extract" (HS Code 30049099) are as follows:

The demand for "Extract" in importing countries is influenced by several factors:

1. Disease Prevalence: High incidences of diseases treatable by "Extract" drive demand. For example, if "Extract" is used in managing cardiovascular conditions, countries with rising cases of heart disease would exhibit increased demand.

2. Government Healthcare Programs: Initiatives aimed at improving public health, such as the Philippines' Universal Health Care Act enacted in 2019, expand access to medications, thereby boosting demand for pharmaceutical imports.

3. Universal Health Coverage Expansion: Countries striving to achieve universal health coverage, like Myanmar's National Health Plan (2017-2021), aim to provide essential medicines to a larger population, increasing the need for imports.

4. WHO Essential Medicines List Procurement: Inclusion of "Extract" in the WHO Essential Medicines List prompts countries to procure it for public health facilities, ensuring availability for critical treatments.

5. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders to ensure cost-effectiveness and supply security. The presence of 591 buyers across 109 countries indicates a competitive market, with opportunities for suppliers to engage in such procurement processes.

Understanding these demand drivers enables suppliers to tailor their strategies, ensuring they meet the specific needs of each market and capitalize on emerging opportunities.